BlinkLab Limited

BlinkLab Limited: Transforming Mental Healthcare through Mobile-based AI App


Australia-based BlinkLab leverages computer vision, artificial intelligence and machine learning by developing an app-enabled, smartphone-based diagnostic tool for evaluating children with neurodevelopmental conditions such as autism and ADHD. The app turns the mobile phone into a medical device for an effortless way of conducting remote and rapid tests.

The BlinkLab Test aims to perform neurobehavioural testing free from facial instruments or other fixed location equipment. This AI-based platform is designed to be used at home or in similar environments, independently or with the assistance of a caregiver while following instructions from the mobile device application.

Blinklab test

In collaboration with Princeton University in the US and Erasmus Medical Center in the Netherlands, Blinklab Test is initially developed as a prescription diagnostic aid to healthcare professionals (HCP). BlinkLab will need to complete a pivotal registrational study and subsequently apply for FDA registration and reimbursement for the tests.

Company Highlights

  • Australia-based BlinkLab is focused on transforming mental healthcare through an AI-enabled smartphone application, a breakthrough technology developed at Princeton University.
  • The company’s innovative approach leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention.
  • Once approved by the regulators, this cutting-edge digital technology is poised to capture the imagination of both investors and major pharmaceutical companies, eager to embrace transformative solutions in healthcare.
  • BlinkLab is led by an experienced management team and leading experts in the field of machine learning, autism and brain development bridging the most advanced technological innovations with groundbreaking scientific research. The company is chaired by Brian Leedman, an experienced biotechnology entrepreneur and founder of ResApp Health, a digital diagnostic company recently acquired by Pfizer.

This BlinkLab is part of a paid investor education campaign.*

Click here to connect with BlinkLab to receive an Investor Presentation

The Conversation (0)
AI visualization.

Tech 5: AI Takes Center Stage at CES, NVIDIA Unveils Cosmos Platform

Global markets were turbulent this week on speculation about US President-elect Donald Trump's trade policies.

Initial gains on Monday (January 6), driven by rumors of less aggressive tariffs, were followed by a mixed performance as the Consumer Electronics Show (CES) kicked off in Las Vegas, Nevada, and investors awaited key economic data.

Keep up with the latest developments in the world of tech with the Investing News Network.

Keep reading...Show less
A microchip with a US flag.

Micron to Expand in Singapore with US$7 Billion AI Chip-packaging Facility

Micron Technology (NASDAQ:MU) announced a US$7 billion investment to build a high-bandwidth memory (HBM) chip-packaging facility in Singapore to meet rising global demand for artificial intelligence (AI) technology.

The facility, which will be adjacent to the US-based semiconductor manufacturer's existing manufacturing site in Singapore, broke ground this week and is scheduled to begin operations by 2026.

Designed to enhance the company’s advanced chip-packaging capabilities, the plant is expected to create 1,400 jobs initially, with the potential to generate up to 3,000 positions as operations scale by 2027.

Keep reading...Show less
BlinkLab

Positive Outcome from FDA Pre-Submission Meeting

BlinkLab Achieves Pivotal Step Towards FDA Approval for Autism Diagnostic App

BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”), an innovative digital healthcare company is pleased to announce a positive outcome from its Pre-Submission meeting with the FDA yesterday. The FDA has confirmed the study design and data requirements in order to achieve 510(k) clearance and subsequently launch the diagnostic app in the U.S. The Company plans to complete both programs within 12-16 months after the necessary approvals and site engagements have been secured.

Keep reading...Show less
Man at laptop with AI symbols superimposed.

AI Market Forecast: Top Trends for AI in 2025

The United Nations has designated 2025 as the year of quantum science and technology, highlighting the profound impact that technological advancements are poised to have on the world.

The increasing prevalence of artificial intelligence (AI) across a wide array of industries has spurred significant investment in the sector over the last two years as the world's largest tech firms jump in. As AI continues to evolve, many investors are wondering if 2025 will be a pivotal year when these investments begin to show significant returns.

From its impact on stock market valuations to its transformative potential across industries, here the Investing News Network delves into the key trends and developments that are shaping the future of AI.

Keep reading...Show less
Rocketboots Limited

RocketBoots Limited (ASX: ROC) – Reinstatement to Quotation

Description

The suspension of trading in the securities of RocketBoots Limited (‘ROC’) will be lifted immediately following the release by ROC of an announcement regarding the details of the capital raise, board changes and remuneration updates.

Keep reading...Show less
Rocketboots Limited

RocketBoots Successfully Completes Capital Raise and Board Changes; Positioned to Deliver International Expansion in 2025

Artificial Intelligence software company RocketBoots Limited (ASX:ROC) (RocketBoots or the Company), is pleased to announce the appointment of Mr Roy McKelvie as Chairman, to guide the company through a period of material scaling. Mr McKelvie will invest $200k in RocketBoots, subject to shareholder approval, and cornerstone a raise for $500k at $0.085 per share (before costs) with other sophisticated investors (Placement).

Keep reading...Show less

Latest Press Releases

Related News

×